 |
|
|
| |
Impact of Hepatoprotective Medications on the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Hepatitis C Virus Genotype 1b-infected Asian Patients With and Without Cirrhosis in the ONYX-I and -II Studies
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Wan-Long Chuang1, Yan Luo2, Jeong Heo3, Gui-Qing Wang4, Ming-Lung Yu5, Yoon Jun Kim6, Qing Xie7, Cheng-Yuan Peng8, Mingxiang Zhang9, Yan Huang10, Sarah Kopecky-Bromberg2, Wenjing Lu2, Linda M Fredrick2, Niloufar Mobashery2, Lai Wei11
1Kaohsiung Medical University, Kaohsiung City, Taiwan; 2AbbVie Inc., North Chicago, Illinois, United States; 3Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute,
Pusan National University Hospital, Busan, Republic of Korea; 4Peking University First Hospital, Beijing, China; 5Department of Internal Medicine, and Hepati ti s Center, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan; 6Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea (the Republic of); 7Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China; 8China Medical University Hospital, Taichung, Taiwan; 9The Sixth People's Hospital of Shenyang, Shenyang, China; 10Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, PR China; 11Peking University People's Hospital, Beijing
|
| |
|
|
|
|
|
